Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2Endocrine 1

Conditions

Breast Neoplasms 257Neoplasms 225Carcinoma, Non-Small-Cell Lung 206Colorectal Neoplasms 148Prostatic Neoplasms 142Lung Neoplasms 116Neoplasm Metastasis 106Ovarian Neoplasms 103Multiple Myeloma 98Pancreatic Neoplasms 89Leukemia, Myeloid, Acute 79Squamous Cell Carcinoma of Head and Neck 75Endometrial Neoplasms 65Melanoma 64Stomach Neoplasms 60Recurrence 59Glioblastoma 57Brain Neoplasms 56Urinary Bladder Neoplasms 51Carcinoma, Hepatocellular 51Triple Negative Breast Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma 48Head and Neck Neoplasms 47Carcinoma, Renal Cell 46Hematologic Neoplasms 44Esophageal Neoplasms 43Colonic Neoplasms 43Uterine Cervical Neoplasms 42Glioma 42

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hereditary leiomyomatosis and renal cell cancer × 30 days × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT00001238 2026-05-22

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
5,000 enrolled
EndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡